Published on 29 November 2022
2022/2 GaBI Journal Table of Contents
1.018 views
Published on 29 November 2022
1.018 views
Published on 29 November 2022
796 views
Published on 24 November 2022
bioequivalence, new branded generics, pharmacokinetics, sitagliptin
DOI: 10.5639/gabij.2023.1201.003
3.150 views
Published on 26 September 2022
Author(s): Mihaela Buda, PhD
flexibility, infliximab, monographs, pharmacopoeia, public standards, reference preparations
DOI: 10.5639/gabij.2022.1103.017
4.480 views
Published on 08 September 2022
Author(s): Professor James C Robinson, PhD, MPH
biosimilars, Germany, healthcare costs, Italy, medicine prices, social trust
DOI: 10.5639/gabij.2022.1103.015
4.859 views
Published on 08 September 2022
biosimilars, interchangeability, substitution, switching, US
DOI: 10.5639/gabij.2022.1103.016
4.094 views
Published on 08 September 2022
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2022.1102.008
1.266 views
Published on 19 August 2022
Author(s): Richard L Easton, BSC (Hons), DIC, PhD
analytics, biosimilars, functional testing, orthogonality, structural characterization
DOI: 10.5639/gabij.2022.1102.013
1.666 views
Published on 19 August 2022
Author(s): Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
biosimilars, health policies, physicians, prescribing, uptake
DOI: 10.5639/gabij.2022.1103.018
7.017 views
Published on 01 August 2022
biosimilars, interchangeability, logarithmic transformation, statistical evaluation
DOI: 10.5639/gabij.2022.1102.010
2.815 views
Published on 19 July 2022
Australia, interchangeability, substitution
DOI: 10.5639/gabij.2022.1102.009
3.410 views
Published on 24 June 2022
Author(s): Federico J Piñeiro, Pharm, MPH, Fernández Argüelles Rogelio Alberto, Pharm, PhD
AstraZeneca, Big Pharma, biosimilars, chiral switch, esomeprazol, generics
DOI: 10.5639/gabij.2022.1102.011
8.499 views